Liver Cancer Treatment
Liver Cancer Treatment
Liver cancer treatment has to win two fights at once: against the tumour, and for the liver tissue that is left. Every option below is chosen with both in view.
How the stage shapes the choice
There is no single best treatment for liver cancer — there is a best treatment for a particular tumour in a particular liver. The table below shows where each stage usually starts; almost every row has exceptions, and the exceptions are exactly what a multidisciplinary review exists to find.
| Stage | Where treatment usually starts |
|---|---|
| Very early and early | Removal of the tumour by surgery, or destruction in place by ablation when surgery is not suitable or not advisable. Transplantation is considered for selected patients whose liver disease itself is advanced. The aim is cure. |
| Intermediate | Interventional treatment delivered through the tumour's blood supply — TACE, drug-eluting TACE or hepatic arterial infusion — often repeated over several sessions. Where the tumours shrink enough, surgery may become possible afterwards. |
| Advanced | Systemic treatment: targeted therapy, immunotherapy combinations, or both, with local treatment added at specific sites when it helps — for example radiosurgery to tumour inside the portal vein. |
| End stage | Treatment directed at comfort, symptom control and quality of life, with active involvement of hepatology and palliative care rather than the withdrawal of care. |
Guideline frameworks differ slightly between regions; the recommendation for an individual patient is made after review of imaging, liver function and general condition.
Surgery: removal, and the volume that is left behind
Removing the tumour offers the best chance of long-term control when it is technically possible and the remaining liver can take over. The limiting factor is rarely the operation itself but the organ: in a scarred liver, removing too much tissue risks liver failure after surgery, which is why the size of the future liver remnant is calculated deliberately rather than estimated.
Two techniques help. A robotic-assisted precision hepatectomy gives the surgeon a magnified three-dimensional view and fully articulated instruments, allowing the tumour to be separated along exact planes while sparing vessels, bile ducts and healthy liver units — useful when the margin between tumour and vital structure is narrow. Where the planned remnant is too small, the liver can be encouraged to grow before the operation, using a staged approach that lets the healthy side enlarge first, so that the definitive operation becomes safe.
Transplantation is a different answer to the same problem: for a patient whose liver disease is itself advanced, replacing the organ treats both the cancer and the cirrhosis. It is offered only within accepted criteria for tumour number, size and absence of vascular invasion, because those criteria are what predict that the cancer will not return quickly. Assessment also weighs donor availability and the patient's general condition.
Ablation: destroying small tumours in place
Ablation destroys a tumour by heating it with radiofrequency or microwave energy, or by freezing it. A needle is placed into the lesion under imaging guidance and the tissue is killed from within, without removing any part of the liver. For small tumours the results are competitive with surgery, and the trade-off is favourable in a liver with limited reserve.
Who it suits best
Small, accessible tumours, typically up to about three centimetres, and often when there are only one or two of them. Also used where surgery is refused, or where the liver cannot tolerate resection.
Why patients choose it
No abdominal incision and, in many cases, a short stay — sometimes an overnight admission. Because no liver tissue is removed, function is preserved, which matters greatly in cirrhosis.
What to know
Complete destruction depends on seeing the whole tumour, so lesions near large vessels, the diaphragm or the bowel may be treated differently. Imaging after the procedure confirms whether the treated area is clear.
Interventional oncology: treating through the blood supply
Liver tumours draw blood mainly from the hepatic artery, while normal liver tissue draws most of its supply from the portal vein. That difference is exploited by interventional treatment: drugs and blocking material can be delivered into the tumour's arterial supply, reaching the cancer in far higher concentration than an intravenous infusion would allow while sparing the surrounding liver. Nothing is removed and no general anaesthetic is needed.
Blocking the supply: TACE and related techniques
"There are several tumours, or they are too large to remove. What can be done about them?"
Conventional TACE and drug-eluting TACE combine an artery-blocking agent with chemotherapy delivered directly into the tumour. Where continuous delivery is preferred, hepatic arterial infusion chemotherapy gives prolonged high-dose regional treatment. These are usually given as repeated sessions several weeks apart, with imaging between them to judge response. At our Guangzhou hospital the interventional team has performed more than 17,000 TACE procedures between 2023 and 2025, which is why difficult vascular anatomy is familiar rather than exceptional.
Precision tools used with it
"Is there something that works at the edge of what the tumour can tolerate?"
Where a tumour needs a local boost, image-guided iodine-125 seed implantation places tiny radioactive sources inside or next to the lesion, delivering local dose over weeks, and tumour hyperthermia is used to make malignant cells more vulnerable to the treatments given alongside it. These are chosen for specific anatomical situations rather than offered to everyone, and are planned by the same team that performs the arterial procedures.
Radiosurgery: when the tumour is in a difficult place
Modern radiotherapy is not a long course of daily treatment for every patient. Stereotactic techniques deliver a small number of high-precision sessions, and the liver is well suited to them when the tumour is small and the liver reserve is limited.
The hardest problem in this area is movement: the liver rises and falls with every breath. The sixth-generation CyberKnife M6 tracks that motion in real time and adjusts each beam accordingly, so the dose follows the tumour rather than a prediction of where it should be. Two groups benefit most: patients whose liver function is too poor for any operation, and patients whose tumour has grown into the portal vein. A portal vein tumour thrombus used to mean there was nothing left to offer; focused radiosurgery can treat the thrombus inside the vessel while sparing its wall, and combining it with systemic therapy has produced meaningful shrinkage in patients previously described as untreatable.
Typically 1–5 sessions
Outpatient treatment, no anaesthetic and no incision. Most patients return to their accommodation the same day and can travel home soon after the course finishes.
Also used after other treatment
A residual area after TACE, a small recurrence at the edge of a previous treatment site or a focus of disease elsewhere in the liver can be treated without repeating an operation.
Combined, not competing
Radiosurgery is frequently given alongside systemic treatment, and the sequencing — which comes first, and by how long — is decided by the panel rather than by a single specialty.
Targeted therapy and immunotherapy
Systemic treatment reaches cancer throughout the liver and beyond it, which is why it is the backbone of care for advanced disease and an important part of treatment before or after surgery or interventional therapy in selected patients.
Two families of drugs are used, often together. Targeted agents interfere with the signals that drive tumour growth and with the blood vessels feeding it; several generations are in routine use. Immunotherapy removes some of the brake that tumours apply to the immune system, and combinations of an immune drug with a targeted or antibody-based agent have become standard first-line options. China's drug development in this field has moved quickly: the combination of camrelizumab with apatinib, developed here, is recognised in NCCN, ESMO and CSCO guidelines, and later-line targeted drugs and bispecific antibodies are in routine clinical use. For a patient whose first treatment has stopped working, that matters — the next question is not whether a second line exists, but which one fits.
What guides the choice
Liver function, prior treatment, the pattern of spread, and tumour testing. Because many systemic drugs are cleared by the liver, dose and choice both depend on how well it is working — which is why hepatology sits in the same discussion as oncology. Where standard options are exhausted, molecular testing can identify a clinical trial matched to the tumour's alterations.
What to expect in practice
Treatment is given in cycles with imaging and blood tests at planned intervals, and side effects are managed rather than simply endured. Response is judged on scans and tumour markers together, and a treatment that is not working is changed rather than continued out of habit. Where the same drug is available at home, part of the course can be delivered locally under a written handover plan.
Supportive and integrative care
Liver cancer treatment is hard on a liver that was already struggling, so supportive care is part of the plan rather than an add-on. Antiviral treatment continues throughout where hepatitis B is present, because suppressing the virus protects the liver the treatment depends on. Nutrition, fluid and diuretic management, control of ascites and encephalopathy, and pain relief all have dedicated input. Integrative programmes including traditional Chinese medicine run alongside mainstream treatment, with herbal formulas used to support remaining liver function and to ease treatment-related nausea, fatigue and bone-marrow suppression, and acupuncture for symptom control. Every integrative plan is coordinated with the oncology team rather than prescribed in parallel.
Seven specialties, one plan
A single recommendation, delivered in 48 hours
Liver cancer is the disease in which single-department decisions are most often wrong: the best answer may be surgical, interventional, radiosurgical, systemic or a sequence of them, and the right order depends on liver function as much as on the tumour. Hepatobiliary surgery, interventional radiology, medical oncology, radiation oncology, hepatology, radiology and pathology review each case together and issue one plan. Upload your records and receive that plan, in writing, within 48 hours of the file being complete.